👤 Jingwan Wu

🔍 Search 📋 Browse 🏷️ Tags ❤️ Favourites ➕ Add 🧪 BiometalDB 🧬 Extraction
1732
Articles
1210
Name variants
Also published as: Aimin Wu, Alexander T H Wu, Alice Ying-Jung Wu, An Guo Wu, An-Chih Wu, An-Dong Wu, An-Hua Wu, An-Li Wu, An-Xin Wu, Andong Wu, Anguo Wu, Anke Wu, Anna H Wu, Anping Wu, Anshi Wu, Anyi Wu, Anyue Wu, Anzhou Wu, B Wu, Baiyan Wu, Baochuan Wu, Baojian Wu, Baojin Wu, Baoqin Wu, Beier Wu, Beili Wu, Ben J Wu, Bian Wu, Biaoliang Wu, Bifeng Wu, Bill X Wu, Bin Wu, Binbin Wu, Bing Wu, Bing-Bing Wu, Bingjie Wu, Binxin Wu, Biwei Wu, Bo Wu, Boquan Wu, Buling Wu, C Wu, C-H Wu, Cai-Qin Wu, Caihong Wu, Caisheng Wu, Caiwen Wu, Catherine A Wu, Chang-Jiun Wu, Changchen Wu, Changjie Wu, Changjing Wu, Changwei Wu, Changxin Wu, Changyu Wu, Chao Wu, Chao-Liang Wu, Chaoling Wu, Chaowei Wu, Chen Wu, Chen-Lu Wu, Cheng Wu, Cheng-Chun Wu, Cheng-Hsin Wu, Cheng-Hua Wu, Cheng-Jang Wu, Cheng-Jun Wu, Cheng-Yang Wu, Chengbiao Wu, Chengqian Wu, Chengrong Wu, Chengwei Wu, Chengxi Wu, Chengyu Wu, Chenyang Wu, Chew-Wun Wu, Chi-Chung Wu, Chi-Hao Wu, Chi-Jen Wu, Chia-Chang Wu, Chia-Chen Wu, Chia-Ling Wu, Chia-Lung Wu, Chia-Zhen Wu, Chiao-En Wu, Chieh-Jen Wu, Chieh-Lin Stanley Wu, Chien-Sheng Wu, Chien-Ting Wu, Chih-Ching Wu, Chih-Chung Wu, Chih-Hsing Wu, Ching-Yi Wu, Cho-Kai Wu, Chong Wu, Chongming Wu, Choufei Wu, Chris Y Wu, Chuan-Ling Wu, Chuang Wu, Chuanhong Wu, Chun Wu, Chun-Chieh Wu, Chun-Hua Wu, Chunfu Wu, Chung-Yi Wu, Chunru Wu, Chunshuai Wu, Chunyan Wu, Colin Chih-Chien Wu, Colin O Wu, Cong Wu, Congying Wu, Constance Wu, Cuiling Wu, Cuiyan Wu, D I Wu, D P Wu, D Wu, Da-Hua Wu, Dai-Chao Wu, Dan Wu, Dan-Chun Wu, Dandan Wu, Danhong Wu, Danni Wu, Daoyuan Wu, Dapeng Wu, Daqing Wu, Daren Wu, David Wu, Daxian Wu, De Wu, De-Fu Wu, Deguang Wu, Dengying Wu, Depei Wu, Depeng Wu, Deqing Wu, Di Wu, Diana H Wu, Diana Wu, Dianqing Wu, Ding Lan Wu, Dirong Wu, Dishan Wu, Disheng Wu, Do-Bo Wu, Dong Wu, Dong-Bo Wu, Dong-Fang Wu, Dong-Feng Wu, Donglin Wu, Dongmei Wu, Dongping Wu, Dongsheng Wu, Dongyan Wu, Dongzhe Wu, Douglas C Wu, Duojiao Wu, Ed Xuekui Wu, Eugenia Wu, Fan Wu, Fanchang Wu, Fang Wu, Fang-Tzu Wu, Fangge Wu, Fanggeng Wu, Fei Wu, Fei-Fei Wu, Feifei Wu, Fenfang Wu, Feng Wu, Fengming Wu, Fengying Wu, Fong-Li Wu, G Wu, G X Wu, Gaige Wu, Gang Wu, Gaojun Wu, Ge-ru Wu, Gen Sheng Wu, Gen Wu, Geng-ze Wu, Geping Wu, Geting Wu, Geyan Wu, Grace F Wu, Guang-Bo Wu, Guang-Liang Wu, Guang-Long Wu, Guanggeng Wu, Guangjie Wu, Guangming Wu, Guangrun Wu, Guangsen Wu, Guangxi Wu, Guangxian Wu, Guangyan Wu, Guangzhen Wu, Guanhui Wu, Guanming Wu, Guanrong Wu, Guanxian Wu, Guanyi Wu, Guanzhao Wu, Guanzhong Wu, Gui-Qin Wu, Guifen Wu, Guifu Wu, Guihua Wu, Guiping Wu, Guixin Wu, Guizhen Wu, Guo-Chao Wu, Guofeng Wu, Guohao Wu, Guojun Wu, Guoli Wu, Guoping Wu, Guoqing Wu, Guorong Wu, Guoyao Wu, H J Wu, H Wu, Hai-Ping Wu, Hai-Yan Wu, Hai-Yin Wu, Haibin Wu, Haidong Wu, Haihu Wu, Haijiang Wu, Haijing Wu, Hailong Wu, Haiping Wu, Haishan Wu, Haisu Wu, Haiwei Wu, Haixia Wu, Haiyan Wu, Haiying Wu, Haiyun Wu, Han Wu, Han-Jie Wu, Hang Wu, Hanyu Wu, Hao Wu, Hao-Tian Wu, Haoan Wu, Haodi Wu, Haomin Wu, Haoming Wu, Haoxuan Wu, Haoze Wu, He Wu, Hei Man Wu, Hei-Man Wu, Hengyu Wu, Hon-Yen Wu, Hong Wu, Hong-Fu Wu, Hong-Mei Wu, Hongfei Wu, Hongfu Wu, Hongke Wu, Hongliang Wu, Honglin Wu, Hongmei Wu, Hongting Wu, Hongxi Wu, Hongxian Wu, Hongyan Wu, Hongyu Wu, Hsan-Au Wu, Hsi-Chin Wu, Hsien-Ming Wu, Hsing-Chieh Wu, Hsiu-Chuan Wu, Hsueh-Erh Wu, Hua Wu, Hua-Yu Wu, Huan Wu, Huanghui Wu, Huanlin Wu, Huanwen Wu, Huating Wu, Huazhang Wu, Huazhen Wu, Hui Wu, Hui-Chen Wu, Hui-Hui Wu, Hui-Mei Wu, Hui-Xuan Wu, Huijian Wu, Huijuan Wu, Huini Wu, Huisheng Wu, Huiwen Wu, Hung-Tsung Wu, I H Wu, Irene X Y Wu, J W Wu, J Wu, J Y Wu, J-Z Wu, Jamie L Y Wu, Jason H Y Wu, Jason Wu, Jemma X Wu, Jer-Yuan Wu, Jer-Yuarn Wu, Jerry Wu, Ji-Zhou Wu, Jia Wu, Jia-En Wu, Jia-Hui Wu, Jia-Jun Wu, Jia-Qi Wu, Jia-Wei Wu, Jiahang Wu, Jiahao Wu, Jiahui Wu, Jiajin Wu, Jiajing Wu, Jiake Wu, Jiamei Wu, Jian Hui Wu, Jian Wu, Jian-Lin Wu, Jian-Qiu Wu, Jian-Yi Wu, Jiang Wu, Jiang-Bo Wu, Jiang-Nan Wu, Jiangdong Wu, Jianguang Wu, Jiangyue Wu, Jianhui Wu, Jianing Wu, Jianjin Wu, Jianjun Wu, Jianli Wu, Jianliang Wu, Jianmin Wu, Jianming Wu, Jianping Wu, Jianqiang Wu, Jianrong Wu, Jianwu Wu, Jianxin Wu, Jianxiong Wu, Jianyi Wu, Jianying Wu, Jianzhang Wu, Jianzhi Wu, Jianzhong Wu, Jiao Wu, Jiapei Wu, Jiaqi Wu, Jiarui Wu, Jiawei Wu, Jiaxi Wu, Jiaxuan Wu, Jiayi Wu, Jiayu Wu, Jiayuan Wu, Jie Wu, JieQian Wu, Jiexi Wu, Jihui Wu, Jin Wu, Jin'en Wu, Jin-Shang Wu, Jin-Zhen Wu, Jin-hua Wu, Jincheng Wu, Jinfeng Wu, Jing Wu, Jing-Fang Wu, Jing-Wen Wu, Jinghong Wu, Jingjing Wu, Jingtao Wu, Jingyi Wu, Jingyue Wu, Jingyun Wu, Jinhua Wu, Jinhui Wu, Jinjie Wu, Jinjun Wu, Jinmei Wu, Jinqiao Wu, Jinyu Wu, Jinze Wu, Jiong Wu, Jiu-Lin Wu, Joseph C Wu, Joshua L Wu, Ju Wu, Juan Wu, Juanjuan Wu, Juanli Wu, Jugang Wu, Julian Wu, Jun Wu, Jundong Wu, Junduo Wu, June K Wu, June-Hsieh Wu, Junfang Wu, Junfei Wu, Junfeng Wu, Junhua Wu, Junjie Wu, Junjing Wu, Junlong Wu, Junqi Wu, Junqing Wu, Junshu Wu, Junyi Wu, Junyong Wu, Junzheng Wu, Junzhu Wu, Justin C Y Wu, Justin Che-Yuen Wu, K D Wu, K S Wu, Kai-Hong Wu, Kai-Yue Wu, Kailang Wu, Kaili Wu, Kan Wu, Kay L H Wu, Ke Wu, Kebang Wu, Keija Wu, Kejia Wu, Kerui Wu, Kevin Zl Wu, Kuan-Li Wu, Kuen-Phon Wu, Kui Wu, Kuixian Wu, Kun Wu, Kun-Rong Wu, Kunfang Wu, Kunling Wu, Kunsheng Wu, L Wu, L-F Wu, Lai Man Natalie Wu, Lan Wu, Lanlan Wu, Lanxiang Wu, Lecheng Wu, Lei Wu, Leilei Wu, Lesley Wu, Leslie Wu, Li Wu, Li-Hsien Wu, Li-Jun Wu, Li-Ling Wu, Li-Na Wu, Li-Peng Wu, Liang Wu, Liang-Huan Wu, Liangyan Wu, Lianqian Wu, Lichao Wu, Lidi Wu, Lifang Wu, Lifeng Wu, Lihong Wu, Lijie Wu, Lijuan Wu, Lijun Wu, Lili Wu, Limei Wu, Limeng Wu, Lin Wu, Lin-Han Wu, Ling Wu, Ling-Fei Wu, Ling-Ying Wu, Ling-qian Wu, Lingling Wu, Lingqian Wu, Lingxi Wu, Lingxiang Wu, Lingyan Wu, Lingyun Wu, Lingzhi Wu, Linhong Wu, Linmei Wu, Lintao Wu, Linxiang Wu, Linyu Wu, Linzhen Wu, Linzhi Wu, Lipeng Wu, Liping Wu, Liqiang Wu, Liqun Wu, Liren Wu, Lisha Wu, Liting Wu, Litong Wu, Liufeng Wu, Liuting Wu, Liuxin Wu, Liuying Wu, Lixing Wu, Liyan Wu, Liyang Wu, Lizhen Wu, Lizi Wu, Long-Jun Wu, Longting Wu, Lorna Wu, Lulu Wu, Lun Wu, Lun-Gang Wu, Luyan Wu, M Wu, Ma Wu, Man Wu, Man-Jing Wu, Maoqing Wu, Mark N Wu, Matthew A Wu, Maureen Wu, Mei Wu, Mei-Hwan Wu, Mei-Na Wu, Meili Wu, Meina Wu, Meini Wu, Meiqi Wu, Meiqin Wu, Meng Wu, Meng-Chao Wu, Meng-Han Wu, Meng-Hsun Wu, Meng-Ling Wu, Meng-Na Wu, Mengbo Wu, Mengchao Wu, Mengjuan Wu, Mengjun Wu, Mengna Wu, Mengqiu Wu, Mengxue Wu, Mengying Wu, Mengyuan Wu, Mian Wu, Michael C Wu, Min Wu, Min-Jiao Wu, Ming J Wu, Ming Wu, Ming-Der Wu, Ming-Jiuan Wu, Ming-Shiang Wu, Ming-Sian Wu, Ming-Tao Wu, Ming-Yue Wu, Mingfu Wu, Minghua Wu, Mingjie Wu, Mingjun Wu, Mingming Wu, Mingxing Wu, Mingxuan Wu, Minna Wu, Minqing Wu, Minyao Wu, Moxin Wu, Muzhou Wu, N Wu, Na Wu, Na-Qiong Wu, Nan Wu, Nana Wu, Naqiong Wu, Ning Wu, Nini Wu, Niting Wu, P L Wu, Panyun Wu, Paul W Wu, Pei Wu, Pei-Ei Wu, Pei-Ting Wu, Pei-Wen Wu, Pei-Yu Wu, Peih-Shan Wu, Peiyao Wu, Peiyi Wu, Peng Wu, Peng-Fei Wu, Pengfei Wu, Pengjie Wu, Pengning Wu, Pensee Wu, Pin Wu, Ping Wu, Ping-Hsun Wu, Pinglian Wu, Pingxian Wu, Po-Chang Wu, Qi Wu, Qi-Biao Wu, Qi-Fang Wu, Qi-Jun Wu, Qi-Nian Wu, Qi-Yong Wu, Qi-Zhu Wu, Qian Wu, Qian-Yan Wu, Qiang Wu, Qianhu Wu, Qianqian Wu, Qianwen Wu, Qiao Wu, Qiaowei Wu, Qibiao Wu, Qibing Wu, Qihan Wu, Qijing Wu, Qin Wu, Qinan Wu, Qinfeng Wu, Qing Wu, Qing-Qian Wu, Qing-Wu Wu, Qinghua Wu, Qinglan Wu, Qinglin Wu, Qingping Wu, Qingshi Wu, Qinyi Wu, Qiong Wu, Qiqing Wu, Qitian Wu, Qiu Wu, Qiu-Li Wu, Qiuchen Wu, Qiuhong Wu, Qiuji Wu, Qiulian Wu, Qiuliang Wu, Qiuxia Wu, Qiuya Wu, Quanhui Wu, Qunzheng Wu, R M Wu, R Ryanne Wu, R Wu, R-J Wu, Ran Wu, Ray-Chin Wu, Re-Wen Wu, Ren Wu, Ren-Chin Wu, Renhai Wu, Renlv Wu, Renrong Wu, Riping Wu, Rong Wu, Ronghua Wu, Rongjie Wu, Rongling Wu, Rongrong Wu, Ru-Zi Wu, Rui Wu, Ruihong Wu, Ruize Wu, Run Wu, Runda Wu, Runpei Wu, Ruohao Wu, Ruolan Wu, Ruonan Wu, Ruying Wu, S F Wu, S J Wu, S L Wu, S M Wu, S Wu, S-F Wu, Sai Wu, Samuel M Wu, San-pin Wu, Sarah Wu, Sean M Wu, Selena Meiyun Wu, Selwin K Wu, Semon Wu, Sen-Chao Wu, Senquan Wu, Sensen Wu, Shao-Guo Wu, Shao-Ming Wu, Shaofei Wu, Shaohuan Wu, Shaojun Wu, Shaoping Wu, Shaoxuan Wu, Shaoyu Wu, Shaoze Wu, Sheng-Li Wu, Shengde Wu, Shengming Wu, Shengnan Wu, Shengru Wu, Shengxi Wu, Shenhao Wu, Shenyue Wu, Shi-Xin Wu, Shibo Wu, Shih-Ying Wu, Shihao Wu, Shin-Long Wu, Shinan Wu, Shiqi Wu, Shiwen Wu, Shixin Wu, Shiya Wu, Shiyang Wu, Shu Wu, Shuai Wu, Shuang Wu, Shufang Wu, Shugeng Wu, Shuihua Wu, Shuisheng Wu, Shujuan Wu, Shunan Wu, Shuo Wu, Shusheng Wu, Shuting Wu, Shuyan Wu, Shuyi Wu, Shuying Wu, Shwu-Yuan Wu, Shyh-Jong Wu, Si-Jia Wu, Sichen Wu, Sihan Wu, Sihui Wu, Sijie Wu, Sijun Wu, Siming Wu, Siqi Wu, Siyi Wu, Siying Wu, Siyu Wu, Song Wu, Songfen Wu, Su Wu, Su-Hui Wu, Suhua Wu, Sunyi Wu, Szu-Hsien Wu, T Wu, Tangchun Wu, Tao Wu, Teng Wu, Terence Wu, Thomas D Wu, Tian Wu, Tiange Wu, Tianhao Wu, Tianqi Wu, Tiantian Wu, Tianwen Wu, Tianzhi Wu, Ting-Feng Wu, Ting-Ting Wu, Tingchun Wu, Tingqin Wu, Tingting Wu, Tong Wu, Tracy Wu, Tsai-Kun Wu, Tsung-Jui Wu, Tsung-Teh Wu, Tung-Ho Wu, Tzu-Chun Wu, V C Wu, W J Wu, W Wu, Wan-Fu Wu, Wanxia Wu, Wei Wu, Wei-Chi Wu, Wei-Ping Wu, Wei-Xun Wu, Wei-Yin Wu, Weibin Wu, Weida Wu, Weidong Wu, Weihua Wu, Weijie Wu, Weijun Wu, Weiwei Wu, Weizhen Wu, Wen Wu, Wen-Chieh Wu, Wen-Hui Wu, Wen-Jeng Wu, Wen-Juan Wu, Wen-Ling Wu, Wen-Qiang Wu, Wen-Sheng Wu, Wen-Shu Wu, Wenda Wu, Wendy Wu, Wenhui Wu, Wenjie Wu, Wenjing Wu, Wenjuan Wu, Wenjun Wu, Wenlin Wu, Wenqi Wu, Wenqian Wu, Wenqiang Wu, Wenwen Wu, Wenxian Wu, Wenxue Wu, Wenyi Wu, Wenyong Wu, Wenyu Wu, Wenze Wu, William K K Wu, William Ka Kei Wu, Wu-Tian Wu, Wudelehu Wu, Wujun Wu, Wutain Wu, Wutian Wu, Xi Wu, Xi-Chen Wu, Xi-Ze Wu, Xia Wu, Xiahui Wu, Xian-Run Wu, Xianan Wu, Xianfeng Wu, Xiangping Wu, Xiangsheng Wu, Xiangwei Wu, Xiangxin Wu, Xianpei Wu, Xiao Wu, Xiao-Cheng Wu, Xiao-Hui Wu, Xiao-Jin Wu, Xiao-Jun Wu, Xiao-Yan Wu, Xiao-Yang Wu, Xiao-Ye Wu, Xiao-Yuan Wu, Xiaobin Wu, Xiaobing Wu, Xiaodi Wu, Xiaodong Wu, Xiaofan Wu, Xiaofeng Wu, Xiaofu Wu, Xiaohong Wu, Xiaohui Wu, Xiaojiang Wu, Xiaojie Wu, Xiaojin Wu, Xiaojing Wu, Xiaojun Wu, Xiaokang Wu, Xiaoke Wu, Xiaolang Wu, Xiaoli Wu, Xiaoliang Wu, Xiaolin Wu, Xiaoling Wu, Xiaolong Wu, Xiaoman Wu, Xiaomei Wu, Xiaomeng Wu, Xiaomin Wu, Xiaoming Wu, Xiaoping Wu, Xiaoqian Wu, Xiaoqing Wu, Xiaoqiong Wu, Xiaorong Wu, Xiaoting Wu, Xiaotong Wu, Xiaoxing Wu, Xiaoyang Wu, Xiaoying Wu, Xiaoyong Wu, Xiaoyun Wu, Xiayin Wu, Xiexing Wu, Xifeng Wu, Xihai Wu, Xilin Wu, Xilong Wu, Ximei Wu, Xin Wu, Xin-Xi Wu, Xinchun Wu, Xing Wu, Xing-De Wu, Xing-Ping Wu, Xingdong Wu, Xinghua Wu, Xingjie Wu, Xinglong Wu, Xingwei Wu, Xinhe Wu, Xinjing Wu, Xinlei Wu, Xinmiao Wu, Xinran Wu, Xinrui Wu, Xinyan Wu, Xinyang Wu, Xinyi Wu, Xinyin Wu, Xiping Wu, Xiru Wu, Xiu-Zhi Wu, Xiuhua Wu, Xiushan Wu, Xiwei Wu, Xu Wu, Xuan Wu, Xuanqin Wu, Xuanshuang Wu, Xudong Wu, Xue Wu, Xue-Mei Wu, Xue-Yan Wu, Xuefen Wu, Xuefeng Wu, Xueji Wu, Xuekun Wu, Xueling Wu, Xuemei Wu, Xueqian Wu, Xueqing Wu, Xueyan Wu, Xueyao Wu, Xueying Wu, Xueyuan Wu, Xuhan Wu, Xunwei Wu, Xuxian Wu, Y H Wu, Y Q Wu, Y Wu, Y Y Wu, Y-W Wu, Ya Wu, Yadi Wu, Yafei Wu, Yajie Wu, Yalan Wu, Yali Wu, Yan Wu, Yan Yan Wu, Yan-Hua Wu, Yan-Jun Wu, Yan-ling Wu, Yanan Wu, Yanchuan Wu, Yanchun Wu, Yandi Wu, Yang Wu, Yangfeng Wu, Yangna Wu, Yangyu Wu, Yanhong Wu, Yanhua Wu, Yanhui Wu, Yanjing Wu, Yanli Wu, Yanqiong Wu, Yanran Wu, Yansheng Wu, Yanting Wu, Yanxiang Wu, Yanyan Wu, Yanzhi Wu, Yao Wu, Yaohong Wu, Yaohua Wu, Yaojiong Wu, Yaoxing Wu, Yaping Wu, Yaqin Wu, Yaru Wu, Yawei Wu, Yawen Wu, Ye Wu, Yen-Wen Wu, Yetong Wu, Yexiang Wu, Yi Wu, Yi-Cheng Wu, Yi-Fang Wu, Yi-Hua Wu, Yi-Long Wu, Yi-Mi Wu, Yi-Ming Wu, Yi-No Wu, Yi-Syuan Wu, Yi-Xia Wu, Yi-Ying Wu, Yibo Wu, Yichen Wu, Yicheng Wu, Yifan Wu, Yifeng Wu, Yih-Jer Wu, Yih-Ru Wu, Yihan Wu, Yihang Wu, Yihe Wu, Yihua Wu, Yihui Wu, Yijian Wu, Yili Wu, Yillin Wu, Yilong Wu, Yin Wu, Yinan Wu, Ying Wu, Ying-Ting Wu, Ying-Ying Wu, Yingbiao Wu, Yinghao Wu, Yingning Wu, Yingxia Wu, Yingying Wu, Yingzhi Wu, Yipeng Wu, Yiping Wu, Yiqun Wu, Yiran Wu, Yiting Wu, Yiwen Wu, Yixia Wu, Yixuan Wu, Yiyang Wu, Yiyi Wu, Yizhou Wu, Yong Wu, Yong-Hao Wu, Yong-Hong Wu, Yongfa Wu, Yongfei Wu, Yonghui Wu, Yongjiang Wu, Yongmei Wu, Yongqi Wu, Yongqun Wu, You Wu, Yu Wu, Yu'e Wu, Yu-Chih Wu, Yu-E Wu, Yu-Hsuan Wu, Yu-Ke Wu, Yu-Ling Wu, Yu-Ting Wu, Yu-Yuan Wu, Yuan Kai Wu, Yuan Wu, Yuan-de Wu, Yuanbing Wu, Yuanhao Wu, Yuanming Wu, Yuanshun Wu, Yuanyuan Wu, Yuanzhao Wu, Yucan Wu, Yuchen Wu, Yudan Wu, Yue Wu, Yueheng Wu, Yueling Wu, Yueming Wu, Yuen-Jung Wu, Yuesheng Wu, Yuetong Wu, Yuexiu Wu, Yuguang Philip Wu, Yuh-Lin Wu, Yuhong Wu, Yujie Wu, Yujuan Wu, Yukang Wu, Yulian Wu, Yuliang Wu, Yulin Wu, Yumei Wu, Yumin Wu, Yuming Wu, Yun Wu, Yun-Wen Wu, Yuna Wu, Yung-Fu Wu, Yunhua Wu, Yunpeng Wu, Yupeng Wu, Yuqin Wu, Yurong Wu, Yushun Wu, Yuting Wu, Yutong Wu, Yuwei Wu, Yuxian Wu, Yuxiang Wu, Yuxin Wu, Yuyi Wu, Yuyu Wu, Z Wu, Zaihao Wu, Ze Wu, Zelai Wu, Zeng-An Wu, Zhangjie Wu, Zhao-Bo Wu, Zhao-Yang Wu, Zhaofei Wu, Zhaoxia Wu, Zhaoyang Wu, Zhaoyi Wu, Zhaoyuan Wu, Zhe Wu, Zheming Wu, Zhen Wu, Zhen-Qi Wu, Zhen-Yang Wu, Zhenfang Wu, Zhenfeng Wu, Zheng Wu, Zhengcan Wu, Zhengfeng Wu, Zhengliang L Wu, Zhengsheng Wu, Zhenguo Wu, Zhengyu Wu, Zhengzhi Wu, Zhenling Wu, Zhenlong Wu, Zhentian Wu, Zhenyan Wu, Zhenyong Wu, Zhenzhen Wu, Zhenzhou Wu, Zhi-Hong Wu, Zhi-Wei Wu, Zhi-Yong Wu, Zhibing Wu, Zhichong Wu, Zhidan Wu, Zhihao Wu, Zhikang Wu, Zhimin Wu, Zhipeng Wu, Zhiping Wu, Zhiqiang Wu, Zhixiang Wu, Zhiye Wu, Zhong Wu, Zhong-Jun Wu, Zhong-Yan Wu, Zhongchan Wu, Zhonghui Wu, Zhongjun Wu, Zhongluan Wu, Zhongqiu Wu, Zhongren Wu, Zhongwei Wu, Zhongyang Wu, Zhou Wu, Zhou-Ming Wu, Zhourui Wu, Zhuanbin Wu, Zhuokai Wu, Zhuoze Wu, Zhuzhu Wu, Zijun Wu, Ziliang Wu, Zilong Wu, Zimu Wu, Zixiang Wu, Zixuan Wu, Zoe Wu, Zong-Jia Wu, Zongfu Wu, Zongheng Wu, Zujun Wu, Zuping Wu
articles
Yohei Yoshihama, Kyle A LaBella, Eiru Kim +9 more · 2021 · Proceedings of the National Academy of Sciences of the United States of America · National Academy of Sciences · added 2026-04-24
Prostate cancer is a leading cause of cancer-related mortality in men. The widespread use of androgen receptor (AR) inhibitors has generated an increased incidence of AR-negative prostate cancer, trig Show more
Prostate cancer is a leading cause of cancer-related mortality in men. The widespread use of androgen receptor (AR) inhibitors has generated an increased incidence of AR-negative prostate cancer, triggering the need for effective therapies for such patients. Here, analysis of public genome-wide CRISPR screens in human prostate cancer cell lines identified histone demethylase JMJD1C (KDM3C) as an AR-negative context-specific vulnerability. Secondary validation studies in multiple cell lines and organoids, including isogenic models, confirmed that small hairpin RNA (shRNA)-mediated depletion of JMJD1C potently inhibited growth specifically in AR-negative prostate cancer cells. To explore the cooperative interactions of AR and JMJD1C, we performed comparative transcriptomics of 1) isogenic AR-positive versus AR-negative prostate cancer cells, 2) AR-positive versus AR-negative prostate cancer tumors, and 3) isogenic JMJD1C-expressing versus JMJD1C-depleted AR-negative prostate cancer cells. Loss of AR or JMJD1C generates a modest tumor necrosis factor alpha (TNFα) signature, whereas combined loss of AR and JMJD1C strongly up-regulates the TNFα signature in human prostate cancer, suggesting TNFα signaling as a point of convergence for the combined actions of AR and JMJD1C. Correspondingly, AR-negative prostate cancer cells showed exquisite sensitivity to TNFα treatment and, conversely, TNFα pathway inhibition via inhibition of its downstream effector MAP4K4 partially reversed the growth defect of JMJD1C-depleted AR-negative prostate cancer cells. Given the deleterious systemic side effects of TNFα therapy in humans and the viability of JMJD1C-knockout mice, the identification of JMJD1C inhibition as a specific vulnerability in AR-negative prostate cancer may provide an alternative drug target for prostate cancer patients progressing on AR inhibitor therapy. Show less
no PDF DOI: 10.1073/pnas.2026324118
JMJD1C
Chong Yin, Ye Tian, Lifang Hu +6 more · 2021 · Journal of cellular and molecular medicine · Blackwell Publishing · added 2026-04-24
Ageing-related osteoporosis is becoming an emerging threat to human health along with the ageing of human population. The decreased rate of osteogenic differentiation and bone formation is the major c Show more
Ageing-related osteoporosis is becoming an emerging threat to human health along with the ageing of human population. The decreased rate of osteogenic differentiation and bone formation is the major cause of ageing-related osteoporosis. Microtubule actin cross-linking factor 1 (MACF1) is an important cytoskeletal factor that promotes osteogenic differentiation and bone formation. However, the relationship between MACF1 expression and ageing-related osteoporosis remains unclear. This study has investigated the expression pattern of MACF1 in bone tissues of ageing-related osteoporosis patients and ageing mice. The study has further elucidated the mechanism of MACF1 promoting bone formation by inhibiting HES1 expression and activity. Moreover, the therapeutic effect of MACF1 on ageing-related osteoporosis and post-menopausal osteoporosis was evaluated through in situ injection of the MACF1 overexpression plasmid. The study supplemented the molecular mechanisms between ageing and bone formation, and provided novel targets and potential therapeutic strategy for ageing-related osteoporosis. Show less
📄 PDF DOI: 10.1111/jcmm.16579
MACF1
Lifang Hu, Chong Yin, Dong Chen +9 more · 2021 · Cell death and differentiation · Nature · added 2026-04-24
Osteoblast differentiation leading to bone formation requires a coordinated transcriptional program. Osteoblastic cells with low level of microtubule actin crosslinking factor 1 (MACF1) show reduced o Show more
Osteoblast differentiation leading to bone formation requires a coordinated transcriptional program. Osteoblastic cells with low level of microtubule actin crosslinking factor 1 (MACF1) show reduced osteoblast differentiation ability, however, the comprehensive mechanism of MACF1's action remains unexplored. In the current study, we found that MACF1 knockdown suppressed osteoblast differentiation by altering the transcriptome dynamics. We further identified two MACF1-interacted proteins, cyclin-dependent kinase 12 (CDK12) and MYST/Esa1-associated factor 6 (MEAF6), and two MACF1-interacted transcription factors (TFs), transcription factor 12 (TCF12) and E2F transcription factor 6 (E2F6), which repress osteoblast differentiation by altering the expression of osteogenic TFs and genes. Moreover, we found that MACF1 regulated cytoplasmic-nuclear localization of itself, TCF12 and E2F6 in a concentration-dependent manner. MACF1 oppositely regulates the expression of TCF12 and transcription factor 7 (TCF7), two TFs that drive osteoblast differentiation to opposite directions. This study reveals that MACF1, a cytoskeletal protein, acts as a sponge for repressors of osteoblast differentiation to promote osteoblast differentiation and contributes to a novel mechanistic insight of osteoblast differentiation and transcription dynamics. Show less
no PDF DOI: 10.1038/s41418-021-00744-9
MACF1
Yan-Hui Yin, Xin-Hui Zhang, Xiao-Ai Wang +12 more · 2021 · Zoological research · added 2026-04-24
The Dianchi golden-line barbel,
📄 PDF DOI: 10.24272/j.issn.2095-8137.2020.321
MAP2K5
Nan Chen, Shan Song, Zhifen Yang +4 more · 2021 · Journal of diabetes and its complications · Elsevier · added 2026-04-24
In the present study, we investigated the effect of carbohydrate responsive element binding protein (ChREBP) on the TXNIP/oxidative stress and apoptosis in diabetic nephropathy. ChREBP Renal expressio Show more
In the present study, we investigated the effect of carbohydrate responsive element binding protein (ChREBP) on the TXNIP/oxidative stress and apoptosis in diabetic nephropathy. ChREBP Renal expression of ChREBP and thioredoxin-interacting protein (TXNIP) was increased in patients with type 2 diabetes mellitus (T2DM) and diabetic mice. ChREBP deficiency improved renal function, apoptosis as well as endoplasmic reticulum (ER) stress in diabetic mice. In addition, ChREBP deficiency prevented expression levels of TXNIP and NADPH oxidase 4 (Nox4), 8-hydroxydeoxyguanosine (8-OHdG) and heme oxygenase-1 (HO-1) in diabetic kidneys. The increased urinary 8-OHdG level induced by diabetes was also attenuated in ChREBP deficiency mice. Similarly, HG was shown to induce ChREBP expression and nuclear translocation in HK-2 cells. HG-induced apoptosis was inhibited by transfection of ChREBP shRNA plasmid. Moreover, we found that knockdown of ChREBP suppressed HG-induced TXNIP and Nox4 expression, reactive oxygen species (ROS) generation and ER stress in HK-2 cells. Furthermore, TXNIP knockdown effectively abrogated HG-induced apoptosis in HK-2 cells. These results suggest that ChREBP deficiency prevents diabetes-induced apoptosis via inhibiting oxidative stress and ER stress, highlighting ChREBP as a potential therapy target for diabetic nephropathy. Show less
no PDF DOI: 10.1016/j.jdiacomp.2021.108050
MLXIPL
Huiyi Ke, Yu Luan, Siming Wu +2 more · 2021 · Frontiers in endocrinology · Frontiers · added 2026-04-24
In the past several decades obesity has become one of the greatest health burdens worldwide. Diet high in fats and fructose is one of the main causes for the prevalence of metabolic disorders includin Show more
In the past several decades obesity has become one of the greatest health burdens worldwide. Diet high in fats and fructose is one of the main causes for the prevalence of metabolic disorders including obesity. Promoting brown or beige adipocyte development and activity is regarded as a potential treatment of obesity. Mondo family transcription factors including MondoA and carbohydrate response element binding protein (ChREBP) are critical for nutrient-sensing in multiple metabolic organs including the skeletal muscle, liver, adipose tissue and pancreas. Under normal nutrient conditions, MondoA and ChREBP contribute to maintaining metabolic homeostasis. When nutrient is overloaded, Mondo family transcription factors directly regulate glucose and lipid metabolism in brown and beige adipocytes or modulate the crosstalk between metabolic organs. In this review, we aim to provide an overview of recent advances in the understanding of MondoA and ChREBP in sensing nutrients and regulating obesity or related pathological conditions. Show less
📄 PDF DOI: 10.3389/fendo.2021.653972
MLXIPL
Die Hu, Yanhong Guo, Renrong Wu +9 more · 2021 · Arteriosclerosis, thrombosis, and vascular biology · added 2026-04-24
[Figure: see text].
no PDF DOI: 10.1161/ATVBAHA.120.315708
MLXIPL
Nan Chen, Lin Mu, Zhifen Yang +5 more · 2021 · Journal of cellular physiology · Wiley · added 2026-04-24
Lipid deposition caused by the disorder of renal lipid metabolism is involved in diabetic nephropathy (DN). Carbohydrate response element-binding protein (ChREBP) is a key transcription factor in high Show more
Lipid deposition caused by the disorder of renal lipid metabolism is involved in diabetic nephropathy (DN). Carbohydrate response element-binding protein (ChREBP) is a key transcription factor in high glucose-induced cellular fat synthesis. At present, the regulation and mechanism of ChREBP on fat metabolism in diabetic kidneys are still unclear. In this study, we showed that lack of ChREBP significantly improved renal injury, inhibited oxidative stress, lipid deposition, fatty acid synthase (FASN), acetyl-CoA carboxylase (ACC) and thioredoxin-interacting protein (TXNIP) expression, as well as the activity of mammalian target of rapamycin complex 1 (mTORC1) in diabetic kidneys. Meanwhile, ChREBP deficiency upregulated the expression of peroxisome proliferator-activated receptor-α (PPARα), carnitine palmitoyltransferaser 1A (CPT1A) and acyl-coenzyme A oxidase 1 (ACOX1) in diabetic kidneys. In vitro, knockdown of ChREBP attenuated lipid deposition, mTORC1 activation, and expression of FASN and ACC, increased PPARα, CPT1A, and ACOX1 expression in HK-2 cells and podocytes under high glucose (HG) conditions. Moreover, HG-induced lipid deposition, increased expression of FASN and ACC and decreased expression of PPARα, CPT1A, and ACOX1 were reversed by rapamycin, a specific inhibitor of mTORC1, in HK-2 cells. These results indicate that ChREBP deficiency alleviates diabetes-associated renal lipid accumulation by inhibiting mTORC1 activity and suggest that reduction of ChREBP is a potential therapeutic strategy to treat DN. Show less
no PDF DOI: 10.1002/jcp.29890
MLXIPL
Yaping Zhou, Fuliang Cao, Qiang Wu +8 more · 2021 · Journal of agricultural and food chemistry · ACS Publications · added 2026-04-24
Several publications report that octacosanol (OCT) has different biological functions. This study was designed to evaluate the antifatigue effect and molecular mechanism of octacosanol (200 mg/(kg day Show more
Several publications report that octacosanol (OCT) has different biological functions. This study was designed to evaluate the antifatigue effect and molecular mechanism of octacosanol (200 mg/(kg day)) in forced exercise-induced fatigue models of trained male C57BL/6 mice. Results showed that octacosanol ameliorated the mice's autonomic activities, forelimb grip strength, and swimming endurance, and the levels of liver glycogen (LG), muscle glycogen (MG), blood lactic acid (BLA), lactate dehydrogenase (LDH), superoxide dismutase (SOD), and glutathione peroxidase (GSH-Px) were also regulated. Gene analysis results showed that treatment with OCT upregulated 29 genes, while 38 genes were downregulated in gastrocnemius tissue. Gene ontology (GO) analyses indicated that these genes enriched functions in relation to myofibril, contractile fiber, and calcium-dependent adenosinetriphosphatase (ATPase) activity. Octacosanol supplementation significantly adjusted the messenger RNA (mRNA) and protein expression levels related to fatigue performance. Octacosanol has an observably mitigating effect in exercise-induced fatigue models, and its molecular mechanism may be related to the regulation of tripartite motif-containing 63 (Trim63), periaxin (Prx), calcium voltage-gated channel subunit α1 H (Cacna1h), and myosin-binding protein C (Mybpc3) expression. Show less
no PDF DOI: 10.1021/acs.jafc.1c01764
MYBPC3
M Zhang, X L Sun, G X Wu +5 more · 2021 · Zhonghua xin xue guan bing za zhi · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn112148-20210118-00056
MYBPC3
Lichao Liu, Sushma P Shenoy, James W S Jahng +4 more · 2021 · Stem cell research · Elsevier · added 2026-04-24
Hypertrophic cardiomyopathy (HCM) is an inherited heart disease that can cause sudden cardiac death and heart failure. HCM often arises from mutations in sarcomeric genes, among which the MYBPC3 is th Show more
Hypertrophic cardiomyopathy (HCM) is an inherited heart disease that can cause sudden cardiac death and heart failure. HCM often arises from mutations in sarcomeric genes, among which the MYBPC3 is the most frequently mutated. Here we generated two human induced pluripotent stem cell (iPSC) lines from a HCM patient who has a familial history of HCM and his daughter who carries the pathogenic non-coding mutation. All lines show the typical morphology of pluripotent cells, a high expression of pluripotency markers, normal karyotype, and in vitro capacity to differentiate into all three germ layers. These lines provide a valuable resource for studying the molecular basis of HCM and drug screening for HCM. Show less
no PDF DOI: 10.1016/j.scr.2021.102279
MYBPC3
Xuanjing Chen, Dezhi Zou, Xiaoling Chen +2 more · 2021 · Journal of physiology and biochemistry · Springer · added 2026-04-24
Cholesterol efflux from macrophages is the first step of reverse cholesterol transport (RCT), whose increase inhibits cholesterol accumulation and foam cell formation to suppress atherogenesis. Hesper Show more
Cholesterol efflux from macrophages is the first step of reverse cholesterol transport (RCT), whose increase inhibits cholesterol accumulation and foam cell formation to suppress atherogenesis. Hesperetin has been reported to exert several protective effects on cardiovascular diseases, while little is known about the role of hesperetin and its underlying mechanism in macrophage foam cell formation. In this study, we sought to investigate the potential effects of hesperetin on foam cell formation and cholesterol efflux by using human macrophages, focusing on liver X receptor alpha (LXRα) and AMPK. We found that hesperetin treatment reduced foam cell formation, intracellular cholesterol levels and the cholesterol esterification rate, and increased cholesterol efflux in THP-1 macrophages. Hesperetin increased the levels of LXRα protein and its targets, including ABCA1, ABCG1, SR-BI, and phosphorylated-AMPK. Meanwhile, the hesperetin-induced increase in LXRα expression was further increased by the AMPK agonist and inhibited by an AMPK inhibitor. Meanwhile, hesperetin increased the levels of LXRα mRNA and its target genes, all of which were decreased in cells transfected with the AMPKα1/α2 small interfering RNA (siRNA). Furthermore, the hesperetin-induced inhibition of foam cell formation and promotion of cholesterol efflux were decreased by transfection of AMPKα1/α2 siRNA. In conclusions, We are the first to report that hesperetin activate AMPK in THP-1-derived macrophages. This activation upregulats LXRα and its targets, including ABCA1, ABCG1 and SR-BI, which significantly inhibits foam cell formation and promotes cholesterol efflux. Our results highlight the therapeutic potential of hesperetin to possibly reduce foam cell formation. This new mechanism might contribute the anti-atherogenic effects of hesperetin. Show less
no PDF DOI: 10.1007/s13105-020-00783-9
NR1H3
Radika Soysa, Jonathan C Bean, Xia Wu +3 more · 2021 · Journal of immunology (Baltimore, Md. : 1950) · added 2026-04-24
In mice, a subset of cardiac macrophages and Kupffer cells derive from fetal precursors, seed the developing tissues, self-renew locally, and persist into adulthood. In this study we investigated how Show more
In mice, a subset of cardiac macrophages and Kupffer cells derive from fetal precursors, seed the developing tissues, self-renew locally, and persist into adulthood. In this study we investigated how these cells survive acute systemic inflammation. In both tissues, early-derived subsets rapidly responded to acute systemic inflammation by assuming a temporary nonclassical activation state featuring upregulation of both proinflammatory ( Show less
no PDF DOI: 10.4049/jimmunol.2001324
NR1H3
Lin Zhao, Wangrui Lei, Chao Deng +8 more · 2021 · Journal of cellular physiology · Wiley · added 2026-04-24
Liver X receptor α (LXRα; also known as NR1H3), an isoform of LXRs, is a member of the nuclear receptor family of transcription factors and plays essential roles in the transcriptional control of chol Show more
Liver X receptor α (LXRα; also known as NR1H3), an isoform of LXRs, is a member of the nuclear receptor family of transcription factors and plays essential roles in the transcriptional control of cholesterol homeostasis. Previous in-depth phenotypic analyses of mouse models with deficient LXRα have also demonstrated various physiological functions of this receptor within inflammatory responses. LXRα activation exerts a combination of metabolic and anti-inflammatory actions resulting in the modulation and the amelioration of inflammatory disorders. The tight "repercussions" between LXRα and inflammation, as well as cholesterol homeostasis, have suggested that LXRα could be pharmacologically targeted in pathologies such as atherosclerosis, acute lung injury, and Alzheimer's disease. This review gives an overview of the recent advances in understanding the roles of LXRα in inflammation and inflammation-associated diseases, which will help in the design of future experimental researches on the potential of LXRα and advance the investigation of LXRα as pharmacological inflammatory targets. Show less
no PDF DOI: 10.1002/jcp.30204
NR1H3
Chuanyin Li, Tianting Han, Qingrun Li +15 more · 2021 · Nucleic acids research · Oxford University Press · added 2026-04-24
The family of Poly(A)-binding proteins (PABPs) regulates the stability and translation of messenger RNAs (mRNAs). Here we reported that the three members of PABPs, including PABPC1, PABPC3 and PABPC4, Show more
The family of Poly(A)-binding proteins (PABPs) regulates the stability and translation of messenger RNAs (mRNAs). Here we reported that the three members of PABPs, including PABPC1, PABPC3 and PABPC4, were identified as novel substrates for MKRN3, whose deletion or loss-of-function mutations were genetically associated with human central precocious puberty (CPP). MKRN3-mediated ubiquitination was found to attenuate the binding of PABPs to the poly(A) tails of mRNA, which led to shortened poly(A) tail-length of GNRH1 mRNA and compromised the formation of translation initiation complex (TIC). Recently, we have shown that MKRN3 epigenetically regulates the transcription of GNRH1 through conjugating poly-Ub chains onto methyl-DNA bind protein 3 (MBD3). Therefore, MKRN3-mediated ubiquitin signalling could control both transcriptional and post-transcriptional switches of mammalian puberty initiation. While identifying MKRN3 as a novel tissue-specific translational regulator, our work also provided new mechanistic insights into the etiology of MKRN3 dysfunction-associated human CPP. Show less
no PDF DOI: 10.1093/nar/gkab155
PABPC4
Xiang Jiang, Ganggang Wang, Yingyi Liu +8 more · 2021 · Cancer letters · Elsevier · added 2026-04-24
Hepatocellular carcinoma (HCC) is a malignancy found at high frequency around the world. Unfortunately, the scarcity of effective early diagnostic methods invariably results in poor outcomes. Long non Show more
Hepatocellular carcinoma (HCC) is a malignancy found at high frequency around the world. Unfortunately, the scarcity of effective early diagnostic methods invariably results in poor outcomes. Long noncoding RNAs (lncRNAs) are known to regulate the progression of hepatocellular carcinoma (HCC). A novel lncRNA RP11-286H15.1(OTTHUMG00000186042) has been identified and associated with HCC; however, the potential role of RP11-286H15.1 in HCC remains undefined. The transcript abundance of RP11-286H15.1 in 80 pairs of HCC samples and cell lines was evaluated by qRT-PCR analysis. The functional role of RP11-286H15.1 in HCC was tested in vivo and in vitro. The mechanisms underlying the role of RP11-286H15.1 in HCC were explored by RNA pulldown, transcriptome sequencing, and RNA immunoprecipitation (RIP), ubiquitination and fluorescence in situ hybridization (FISH) assays as well as Western blot analysis. The qRT-PCR and FISH assays revealed that RP11-286H15.1 was significantly decreased in HCC, and implied a shorter survival time. RP11-286H15.1 overexpression inhibited HCC cell proliferation and metastasis in vitro and in vivo, whereas RP11-286H15.1 knockdown produced the opposite results. Furthermore, we confirmed that RP11-286H15.1 (620-750 nucleotides) binds to poly(A) binding protein 4 (PABPC4) and promotes its ubiquitination, thus, reducing the stability of TRIM37 and CDC27 mRNAs. Our study demonstrates that a novel lncRNA, RP11-286H15.1, represses HCC progression by promoting PABPC4 ubiquitination. These findings highlight potential therapeutic targets for HCC. Show less
no PDF DOI: 10.1016/j.canlet.2020.11.038
PABPC4
Yiming Lei, Xuan Xu, Huiling Liu +5 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
The hepatitis B virus X protein (HBx) is involved in the process of hepatocellular carcinoma via the activation of various oncogenes. Our previous study indicated that ARBB1 (arrestin beta 1) promotes Show more
The hepatitis B virus X protein (HBx) is involved in the process of hepatocellular carcinoma via the activation of various oncogenes. Our previous study indicated that ARBB1 (arrestin beta 1) promotes hepatocellular carcinogenesis (HCC). However, the role of ARRB1 in HBx-related HCC remains unclear. Herein, we identified that ARRB1 was upregulated by HBx Show less
no PDF DOI: 10.1080/15548627.2021.1917948
PIK3C3
Wenxian Wu, Xiaojing Wang, Yadong Sun +10 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
Macroautophagy/autophagy and necroptosis represent two opposing cellular s tress responses. Whereas autophagy primarily fulfills a cyto-protective function, necroptosis is a form of regulated cell dea Show more
Macroautophagy/autophagy and necroptosis represent two opposing cellular s tress responses. Whereas autophagy primarily fulfills a cyto-protective function, necroptosis is a form of regulated cell death induced via death receptors. Here, we aimed at investigating the molecular crosstalk between these two pathways. We observed that RIPK3 directly associates with AMPK and phosphorylates its catalytic subunit PRKAA1/2 at T183/T172. Activated AMPK then phosphorylates the autophagy-regulating proteins ULK1 and BECN1. However, the lysosomal degradation of autophagosomes is blocked by TNF-induced necroptosis. Specifically, we observed dysregulated SNARE complexes upon TNF treatment; e.g., reduced levels of full-length STX17. In summary, we identified RIPK3 as an AMPK-activating kinase and thus a direct link between autophagy- and necroptosis-regulating kinases. Show less
no PDF DOI: 10.1080/15548627.2021.1899667
PIK3C3
Aiting Wang, Lei Ding, Zhongqiu Wu +7 more · 2021 · The Journal of experimental medicine · added 2026-04-24
Autophagy programs the metabolic and functional fitness of regulatory T (T reg) cells to establish immune tolerance, yet the mechanisms governing autophagy initiation in T reg cells remain unclear. He Show more
Autophagy programs the metabolic and functional fitness of regulatory T (T reg) cells to establish immune tolerance, yet the mechanisms governing autophagy initiation in T reg cells remain unclear. Here, we show that the E3 ubiquitin ligase ZFP91 facilitates autophagy activation to sustain T reg cell metabolic programming and functional integrity. T reg cell-specific deletion of Zfp91 caused T reg cell dysfunction and exacerbated colonic inflammation and inflammation-driven colon carcinogenesis. TCR-triggered autophagy induction largely relied on T reg cell-derived ZFP91 to restrict hyperglycolysis, which is required for the maintenance of T reg cell homeostasis. Mechanistically, ZFP91 rapidly translocated from the nucleus to the cytoplasm in response to TCR stimulation and then mediated BECN1 ubiquitination to promote BECN1-PIK3C3 complex formation. Therefore, our results highlight a ZFP91-dependent mechanism promoting TCR-initiated autophagosome maturation to maintain T reg cell homeostasis and function. Show less
no PDF DOI: 10.1084/jem.20201217
PIK3C3
Guan Yang, Wenqiang Song, Jielin Xu +6 more · 2021 · Cellular & molecular immunology · Nature · added 2026-04-24
The PIK3C3/VPS34 subunit of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex plays a role in both canonical and noncanonical autophagy, key processes that control immune-cell responsiven Show more
The PIK3C3/VPS34 subunit of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex plays a role in both canonical and noncanonical autophagy, key processes that control immune-cell responsiveness to a variety of stimuli. Our previous studies found that PIK3C3 is a critical regulator that controls the development, homeostasis, and function of dendritic and T cells. In this study, we investigated the role of PIK3C3 in myeloid cell biology using myeloid cell-specific Pik3c3-deficient mice. We found that Pik3c3-deficient macrophages express increased surface levels of major histocompatibility complex (MHC) class I and class II molecules. In addition, myeloid cell-specific Pik3c3 ablation in mice caused a partial impairment in the homeostatic maintenance of macrophages expressing the apoptotic cell uptake receptor TIM-4. Pik3c3 deficiency caused phenotypic changes in myeloid cells that were dependent on the early machinery (initiation/nucleation) of the classical autophagy pathway. Consequently, myeloid cell-specific Pik3c3-deficient animals showed significantly reduced severity of experimental autoimmune encephalomyelitis (EAE), a primarily CD4 Show less
no PDF DOI: 10.1038/s41423-020-00589-1
PIK3C3
Shuo Tian, Shouheng Jin, Yaoxing Wu +5 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
Macroautophagy/autophagy, a eukaryotic homeostatic process that sequesters cytoplasmic constituents for lysosomal degradation, is orchestrated by a number of autophagy-related (ATG) proteins tightly c Show more
Macroautophagy/autophagy, a eukaryotic homeostatic process that sequesters cytoplasmic constituents for lysosomal degradation, is orchestrated by a number of autophagy-related (ATG) proteins tightly controlled by post-translational modifications. However, the involvement of reversible ubiquitination in the regulation of autophagy remains largely unclear. Here, we performed a single-guide RNA-based screening assay to investigate the functions of deubiquitinating enzymes (DUBs) in regulating autophagy. We identified previously unrecognized roles of several DUBs in modulating autophagy at multiple levels by targeting various ATG proteins. Mechanistically, we demonstrated that STAMBP/AMSH (STAM-binding protein) promotes the stabilization of ULK1 by removing its lysine 48 (K48)-linked ubiquitination, whereas OTUD7B mediates the degradation of PIK3 C3 by enhancing its K48-linked ubiquitination, thus positively or negatively affects autophagy flux, respectively. Together, our study elaborated on the broad involvement of DUBs in regulating autophagy and uncovered the critical roles of the reversible ubiquitination in the modification of ATG proteins. Show less
no PDF DOI: 10.1080/15548627.2020.1761652
PIK3C3
Guan Yang, Wenqiang Song, J Luke Postoak +5 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
The PIK3C3/VPS34 subunit of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex is a key early player in macroautophagy/autophagy. In this study, we assessed the contribution of PIK3C3 to T Show more
The PIK3C3/VPS34 subunit of the class III phosphatidylinositol 3-kinase (PtdIns3K) complex is a key early player in macroautophagy/autophagy. In this study, we assessed the contribution of PIK3C3 to T cell metabolism and function. We found that Show less
no PDF DOI: 10.1080/15548627.2020.1752979
PIK3C3
Ming-Yue Wu, Le Liu, Er-Jin Wang +15 more · 2021 · Autophagy · Taylor & Francis · added 2026-04-24
NRBF2, a regulatory subunit of the ATG14-BECN1/Beclin 1-PIK3C3/VPS34 complex, positively regulates macroautophagy/autophagy. In this study, we report that NRBF2 is required for the clearance of apopto Show more
NRBF2, a regulatory subunit of the ATG14-BECN1/Beclin 1-PIK3C3/VPS34 complex, positively regulates macroautophagy/autophagy. In this study, we report that NRBF2 is required for the clearance of apoptotic cells and alleviation of inflammation during colitis in mice. NRBF2-deficient mice displayed much more severe colitis symptoms after the administration of ulcerative colitis inducer, dextran sulfate sodium salt (DSS), accompanied by prominent intestinal inflammation and apoptotic cell accumulation. Interestingly, we found that Show less
no PDF DOI: 10.1080/15548627.2020.1741332
PIK3C3
Alexander T H Wu, Bashir Lawal, Li Wei +3 more · 2021 · Pharmaceutics · MDPI · added 2026-04-24
Alzheimer's disease (AD) is the most frequent cause of neurodegenerative dementia and affects nearly 50 million people worldwide. Early stage diagnosis of AD is challenging, and there is presently no Show more
Alzheimer's disease (AD) is the most frequent cause of neurodegenerative dementia and affects nearly 50 million people worldwide. Early stage diagnosis of AD is challenging, and there is presently no effective treatment for AD. The specific genetic alterations and pathological mechanisms of the development and progression of dementia remain poorly understood. Therefore, identifying essential genes and molecular pathways that are associated with this disease's pathogenesis will help uncover potential treatments. In an attempt to achieve a more comprehensive understanding of the molecular pathogenesis of AD, we integrated the differentially expressed genes (DEGs) from six microarray datasets of AD patients and controls. We identified ATPase H+ transporting V1 subunit A ( Show less
no PDF DOI: 10.3390/pharmaceutics13101555
RGS17
Zhicheng Dai, Yuwen Wang, Zhichong Wu +6 more · 2021 · Spine · added 2026-04-24
A genetic case-control study. To investigate whether the variants in BOC, SEC16B, and SH2D1B are sex-specifically and functionally associated with the susceptibility of adolescent idiopathic scoliosis Show more
A genetic case-control study. To investigate whether the variants in BOC, SEC16B, and SH2D1B are sex-specifically and functionally associated with the susceptibility of adolescent idiopathic scoliosis (AIS) in Chinese Han population. A recent genome-wide association study identified three female-specific susceptibility loci of AIS in Japanese population. However, the association of these genes with AIS in other populations remains unclear. Further investigation of the functional role of the three genes was warranted. SNPs rs73235136, rs545608, and rs142502288 were genotyped in 1599 AIS patients and 2985 controls. Paraspinal muscle collected from 40 AIS and 30 lumber disc herniation patients during surgical interventions was used for gene expression analysis. The difference regarding genotype and allele frequency between patients and controls was analyzed by chi-square analysis. Expression of BOC and SEC16B was compared between AIS and lumber disc herniation patients by the Student t test. Pearson correlation analysis was performed to evaluate the relationship between gene expression level and clinical phenotypes. SNPs rs73235136 of BOC and rs545608 of SEC16B were found to be remarkably associated with AIS only in females. Allele C of rs73235136 and allele G of rs545608 could significantly add to the risk of female AIS patients, with an odds ratio of 1.087 and 1.033, respectively. However, there was no significant difference between the male patients and controls regarding genotype or allele frequency of rs73235136 and rs545608. No polymorphism at rs142502288 was detected in either patients or controls, and all the subjects had genotype of AA. Moreover, tissue expression of BOC and SEC16B was significantly lower in AIS patients compared with controls. BOC expression was positively associated with bone mineral contents, and expression of SEC16B was negatively correlated with curve severity in AIS patients. Female-specific variants in BOC and SEC16B were associated with AIS. Expression of BOC and SEC16B was significantly lower in AIS patients. The role of BOC and SEC16B in the development of AIS is worthy of further investigation.Level of Evidence: 3. Show less
no PDF DOI: 10.1097/BRS.0000000000004098
SEC16B
Chia-Chang Wu, Yuan-Hung Wang, Su-Wei Hu +3 more · 2021 · Frontiers in oncology · Frontiers · added 2026-04-24
Dysfunctional transcription machinery with associated dysregulated transcription characterizes many malignancies. Components of the mediator complex, a principal modulator of transcription, are increa Show more
Dysfunctional transcription machinery with associated dysregulated transcription characterizes many malignancies. Components of the mediator complex, a principal modulator of transcription, are increasingly implicated in cancer. The mediator complex subunit 10 (MED10), a vital kinase module of the mediator, plays a critical role in bladder physiology and pathology. However, its role in the oncogenicity, metastasis, and disease recurrence in bladder cancer (BLCA) remains unclear. Thus, we investigated the role of dysregulated or aberrantly expressed MED10 in the enhanced onco-aggression, disease progression, and recurrence of bladder urothelial carcinoma (UC), as well as the underlying molecular mechanism. Using an array of multi-omics big data analyses of clinicopathological data, Our bioinformatics-aided gene expression profiling showed that MED10 is aberrantly expressed in patients with BLCA, is associated with high-grade disease, is positively correlated with tumor stage, and confers significant survival disadvantage. Reanalyzing the TCGA BLCA cohort (n = 454), we showed that aberrantly expressed MED10 expression is associated with metastatic and recurrent disease, disease progression, immune suppression, and therapy failure. Interestingly, we demonstrated that MED10 interacts with and is co-expressed with the microRNA, hsa-miR-590, and that CRISPR-mediated knockout of MED10 elicits the downregulation of miR-590 preferentially in metastatic UC cells, compared to their primary tumor peers. More so, silencing MED10 in SW1738 and JMSU1 UC cell lines significantly attenuates their cell proliferation, migration, invasion, clonogenicity, and tumorsphere formation (primary and secondary), with the associated downregulation of BCL-xL, MKI67, VIM, SNAI1, OCT4, and LIN28A but upregulated BAX protein expression. In addition, we showed that high MED10 expression is a non-inferior biomarker of urothelial recurrence compared with markers of cancer stemness; however, MED10 is a better biomarker of local recurrence than any of the stemness markers. These data provide preclinical evidence that dysregulated MED10/MIR590 signaling drives onco-aggression, disease progression, and recurrence of bladder UC and that this oncogenic signal is therapeutically actionable for repressing the metastatic/recurrent phenotypes, enhancing therapy response, and shutting down stemness-driven disease progression and relapse in patients with BLCA/UC. Show less
no PDF DOI: 10.3389/fonc.2021.744937
SNAI1
X Li, P L Wu, J W Zhu +2 more · 2021 · Zhonghua fu chan ke za zhi · added 2026-04-24
no PDF DOI: 10.3760/cma.j.cn112141-20210610-00315
SNAI1
Yangyang Yang, Binggong Zhao, Linlin Lv +3 more · 2021 · Cell death discovery · Nature · added 2026-04-24
F-box and leucine-rich repeat protein 10 (FBXL10) has been reported to play a regulatory role in the initiation and development of breast cancer. Bioinformatics analyses revealed that FBXL10 may invol Show more
F-box and leucine-rich repeat protein 10 (FBXL10) has been reported to play a regulatory role in the initiation and development of breast cancer. Bioinformatics analyses revealed that FBXL10 may involve in the process of cytoskeleton organization. This research aimed to investigate the function of FBXL10 in epithelial-mesenchymal transition (EMT) and metastasis of breast cancer, and tried to reveal the molecular mechanism involved in this issue. Functional experiments in vitro revealed that FBXL10 promoted the migration and invasion of breast cancer cells through inhibiting E-cadherin expression and inducing EMT. Mechanical studies revealed that FBXL10 could specifically interact with SNAI1, but not Slug or ZEB1. And it promoted the transcriptional repression activity of SNAI1 on CDH1 in breast cancer cells. Furthermore, FBXL10 had a positive role for the deacetylation of SNAI1 by facilitating the interaction between SNAI1 and HDAC1, a dominating deacetylase of SNAI1. And the deacetylated SNAI1 showed a more suppressive ability to inhibit the transcription of E-cadherin. Moreover, mouse models were also conducted to confirm the effect of FBXL10 on the lung metastasis of breast cancer in vivo. Totally, our data revealed that FBXL10 served as a pro-metastatic factor in breast cancer via repressing the expression of E-cadherin and inducing EMT. It may provide a novel regulatory axis in the EMT of breast cancer. Show less
no PDF DOI: 10.1038/s41420-021-00722-7
SNAI1
Bo Dong, Yadi Wu · 2021 · International journal of molecular sciences · MDPI · added 2026-04-24
SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-mesenchymal transition (EMT) but also functions as a driver of cancer progression, including cell invasio Show more
SNAI1, a zinc finger transcription factor, not only acts as the master regulator of epithelial-mesenchymal transition (EMT) but also functions as a driver of cancer progression, including cell invasion, survival, immune regulation, stem cell properties, and metabolic regulation. The regulation of SNAI1 occurs at the transcriptional, translational, and predominant post-translational levels including phosphorylation, acetylation, and ubiquitination. Here, we discuss the regulation and role of SNAI1 in cancer metastasis, with a particular emphasis on epigenetic regulation and post-translational modifications. Understanding how signaling networks integrate with SNAI1 in cancer progression will shed new light on the mechanism of tumor metastasis and help develop novel therapeutic strategies against cancer metastasis. Show less
no PDF DOI: 10.3390/ijms222011062
SNAI1
Tianli Shen, Chenyang Yue, Xingjie Wang +6 more · 2021 · Experimental cell research · Elsevier · added 2026-04-24
Metastatic recurrence remains a major cause of colorectal cancer (CRC) mortality. In this study, we investigated the mechanistic role of nuclear factor of activated T cells 1 (NFATc1) in CRC metastasi Show more
Metastatic recurrence remains a major cause of colorectal cancer (CRC) mortality. In this study, we investigated the mechanistic role of nuclear factor of activated T cells 1 (NFATc1) in CRC metastasis. First, we explored the potential role of NFATc1 in CRC using bioinformatics and hypothesized that NFATc1 might play different roles at different stages of CRC development. Then, we examined the relative expression of NFATc1 in 25 CRC tissues and adjacent normal tissues, and further analyzed the correlation between NFATc1 expression levels and clinical stages in 120 CRC patients. The role of NFATc1 in CRC metastasis and the molecular mechanisms were investigated in both in vitro and in vivo models. Our results showed that the expression of NFATc1 was increased in metastatic CRC tissues and positively associated with clinical stages (stage I vs. stage II, III or IV) of CRC. Overexpression of NFATc1 promoted CRC cell migration, invasion, and epithelial-mesenchymal transition (EMT). Moreover, SNAI1 was verified as the direct transcriptional target of NFATc1 and interacted with SLUG to promote EMT. Remarkably, our lung and liver metastasis mouse model demonstrated that NFATc1 overexpression accelerated CRC metastasis, and treatment with FK506, a calcineurin-NFAT pathway inhibitor, could suppress CRC metastasis in vivo. Taken together, our findings suggest that NFATc1 could transcriptionally activate SNAI1, which in turn interacts with SLUG to mediate EMT to promote CRC metastasis. Thus, making NFATc1 a promising therapeutic target in the treatment of metastatic CRC. Show less
no PDF DOI: 10.1016/j.yexcr.2021.112854
SNAI1